These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34714428)

  • 1. Consideration of quality of life in the health technology assessments of rare disease treatments.
    Nicod E; Meregaglia M; Whittal A; Upadhyaya S; Facey K; Drummond M
    Eur J Health Econ; 2022 Jun; 23(4):645-669. PubMed ID: 34714428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments.
    Nicod E; Lloyd AJ; Morel T; Meregaglia M; Upadhyaya S; Whittal A; Facey K; Drummond M
    Patient; 2023 Jan; 16(1):7-17. PubMed ID: 36217098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
    Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
    Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.
    Meregaglia M; Whittal A; Nicod E; Drummond M
    Pharmacoeconomics; 2020 Jun; 38(6):557-574. PubMed ID: 32152892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of rarity in NICE's health technology appraisals.
    Clarke S; Ellis M; Brownrigg J
    Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
    Morrell L; Wordsworth S; Schuh A; Middleton MR; Rees S; Barker RW
    BMC Health Serv Res; 2018 May; 18(1):393. PubMed ID: 29855313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic literature review of health state utility values in head and neck cancer.
    Meregaglia M; Cairns J
    Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
    Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
    Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.